News

AMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announces that it has entered into a license and supply agreement (LSA) with an undisclosed partner for the commercialization of its goserelin implant in a relevant LATAM country. AMW’s new LATAM partner is active and highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients.

read more

AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer

AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.

read more

EMPLOYEES OF AMW DONATE THE PROCEEDS OF THE TOMBOLA IN THE AMOUNT OF 500 EURO

Employees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen.

read more

Expansion of the partnership between AMW and Zentiva for Western Europe

Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.

read more

AMW GmbH realigns management

Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board and remains associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors Dr. Friedrich Tegel and Philipp Karbach.

read more

AMW GmbH from Warngau continues to grow and founds an advisory board

Meanwhile more than 100 employees are employed at the pharmaceutical companyin Warngau. The specialy pharmaceuticalwas able to develop a generic drug for the contraception ring Nuvaring of MSD to market maturityin addition to the implants Goserelin and Leuprorelin as well as patches Buprenorphin and Rivastigmin,. With this product, AMW is setting new standards in contraception. Furthermorenew products are under development. In order to position itself even better scientifically and technically, AMW founds an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.

read more